Oxford Outcomes, an international health outcomes consultancy, has become a member of SAFE-BioPharma Association, the non-profit association that created and manages the global SAFE-BioPharma® digital identity and signature standard for the pharmaceutical and healthcare industries.
The company provides services that support the drug development lifecycle, including patient-reported outcomes research, health economics, epidemiology, infectious disease research, and translation and linguistic validation. It is headquartered in Oxford, U.K., with offices in Canada and the U.S. Its clients include some of the world’s largest biopharmaceutical companies.
“We joined SAFE-BioPharma in order to reduce the time and cost associated with managing documents. As members we can sign forms and other documents with SAFE-BioPharma digital signatures and virtually eliminate the problems associated with signing, shipping, storing and accessing paper,” said Gareth Ellis, Manager of PRO Linguistic Validation services.
SAFE-BioPharma digital signatures provide superior anti-forgery and legal protection to electronic documents than conventional electronic signatures. The SAFE-BioPharma standard also is used extensively for digital identity management and facilitates interoperability across different information systems.
“Becoming a member of SAFE-BioPharma gives Oxford Outcomes the ability to engage more efficiently with its major pharmaceutical clients,” said Mollie Shields-Uehling, president and CEO, SAFE-BioPharma Association.
Oxford Outcomes, which has around 80 employees worldwide, joined SAFE-BioPharma using the association’s new small-entity pricing.
About Oxford Outcomes (www.oxfordoutcomes.com) Oxford Outcomes, established in 1997, is a leading international health outcomes consultancy with offices in the U.K. (Oxford), Canada (Vancouver and Toronto) and the U.S. (Bethesda, Md. and Morristown, N.J.). The company provides a broad spectrum of specialist services in patient reported outcomes research, health economics, epidemiology, infectious disease research, and translation and linguistic validation.
About SAFE-BioPharma Association (www.safe-biopharma.org) SAFE-BioPharma Association is the non-profit association that created and manages the SAFE-BioPharma® digital identity and signature standard for the pharmaceutical and healthcare industries.
The Association’s members include:
- Abbott (NYSE: ABT)
- Amarin Corp. (NASDAQ: AMRN)
- Amgen (NASDAQ: AMGN)
- AstraZeneca (NYSE: AZN)
- Bristol-Myers Squibb (NYSE:BMY)
- GlaxoSmithKline (NYSE: GSK)
- Johnson & Johnson (NYSE: JNJ)
- Eli Lilly (NYSE: LLY)
- McDougall Scientific
- Merck (NYSE:MRK)
- National Notary Association
- Novartis (NYSE: NVS)
- Oxford Outcomes
- Pfizer (NYSE: PFE)
- Premier Inc.
- Sanofi-Aventis (NYSE:SNY)
- ScheringPlough-Organon (NYSE: SGP)
- SNAP Diagnostics
SAFE-BioPharma® is a trademark of SAFE-BioPharma Association. Any use of this trademark requires approval from SAFE-BioPharma Association.